Albert Berger, MBA

Albert Berger is the Chief Executive Officer of United States Drug Testing Laboratory (USDTL), bringing decades of leadership experience in the diagnostics and drug testing industries. Before joining USDTL, Albert was CEO of Confirm Biosciences, a leading provider of high-quality diagnostic screening solutions for employers, retailers, and government agencies. Under his leadership, Confirm Biosciences achieved significant milestones, including its acquisitions by Clinical Reference Lab in 2021 and Healgen Scientific in 2024.

 

Before that, he was the CEO of Redwood Toxicology Laboratory, the world’s largest single-site drug testing laboratory, offering an extensive portfolio of drug and alcohol testing solutions, including visual-read screening devices and laboratory testing services. During his tenure, he successfully led the 2008 acquisition of Redwood Toxicology by Alere (NYSE: ALR) on behalf of shareholders and private equity ownership group American Capital Strategies (NASDAQ: ACAS). In 2006, he also played a key role in negotiating Redwood Toxicology’s acquisition by American Capital Strategies (ACAS). Albert held management positions at Tyco Electronics and United Parcel Service earlier in his career, further strengthening his expertise in operational leadership and strategic growth.

 

He holds an MBA from Saint Mary’s College and a BS in Organizational Communication from the Hugh Downs School of Communication at Arizona State University.